---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-24-000064"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:47:11.991492+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics announces positive Phase 3 data for LNZ100 in China presbyopia trial

## Summary
- Primary endpoint met: 74% achieved ≥3-line improvement at 3 hours (p<0.0001 vs vehicle).
- Rapid onset: 69% achieved ≥3-line improvement at 30 minutes; 84% achieved ≥2-line improvement.
- Long duration: 30% maintained ≥3-line improvement at 10 hours; 61% achieved ≥2-line improvement.
- No serious treatment-related adverse events observed; well-tolerated in 300-patient study.
- LNZ100 is aceclidine-based eye drop; NDA already accepted by FDA for U.S. market.

## SEC filing metadata
- accession: 0001815776-24-000064
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000064/0001815776-24-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000064/lenz-20241027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-24-000064
- JSON: https://secwatch.observer/filing/0001815776-24-000064.json
- Plain text: https://secwatch.observer/filing/0001815776-24-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.